10:23 AM EDT, 03/31/2025 (MT Newswires) -- MediPharm Labs ( MEDIF ) , a pharmaceutical company specialized in precision-based cannabinoids, on Monday said fourth-quarter operating loss narrowed as revenue increased 32%

For Q4, the company said operating loss narrowed to $1.8 million, from near $2.71 million in the prior year period.

Revenue jumped 32% to $12 million over the same period. MediPharm ( MEDIF ) said the contribution from the international revenue segment increased to 54%, from 27% in the previous corresponding quarter.

Among other highlights, it said an Adjusted EBITDA loss of $0.1 million improved $1.5 million or 94% versus Q4 2023. It cited a "strong" balance sheet, relative to many peer companies, with $11.7 million of cash and materially debt-free.

The company's shares were last seen down $0.005, to $0.095, on the Toronto Stock Exchange.

Price: 0.10, Change: -0.01, Percent Change: -5.00